Enzo Biochem (NYSE:ENZ) released its quarterly earnings data on Monday, March 12th. The medical research company reported ($0.04) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.01) by ($0.03), Bloomberg Earnings reports. The company had revenue of $26.95 million for the quarter, compared to analysts’ expectations of $27.35 million. Enzo Biochem had a negative net margin of 1.38% and a negative return on equity of 2.95%.
Shares of ENZ stock traded up $0.09 during trading on Wednesday, hitting $6.33. The company had a trading volume of 57,551 shares, compared to its average volume of 179,927. Enzo Biochem has a 1 year low of $6.11 and a 1 year high of $12.04.
In related news, CEO Elazar Rabbani sold 14,000 shares of Enzo Biochem stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total value of $108,500.00. Following the completion of the transaction, the chief executive officer now owns 1,867,202 shares in the company, valued at approximately $14,470,815.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Barry W. Weiner sold 11,000 shares of Enzo Biochem stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $7.75, for a total value of $85,250.00. Following the completion of the transaction, the chief financial officer now owns 1,313,111 shares of the company’s stock, valued at approximately $10,176,610.25. The disclosure for this sale can be found here. 8.90% of the stock is owned by insiders.
Separately, ValuEngine lowered Enzo Biochem from a “hold” rating to a “sell” rating in a research note on Thursday, March 1st.
ILLEGAL ACTIVITY WARNING: This report was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2018/03/21/enzo-biochem-enz-posts-quarterly-earnings-results-misses-expectations-by-0-03-eps.html.
Enzo Biochem Company Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.